Akihito Tsuji

10.7k citations

184 papers · 2.8k indexed · 1 hit paper · h-index 24

Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 18
Oncology top 1%
- Colorectal Cancer Treatments and Studies 122
- Cancer Treatment and Pharmacology 48
- Pancreatic and Hepatic Oncology Research 17
Pulmonary and Respiratory Medicine top 1%
- Gastric Cancer Management and Outcomes 83
- Lung Cancer Treatments and Mutations 38
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 21
Pathology and Forensic Medicine top 5%
Surgery
- Cholangiocarcinoma and Gallbladder Cancer Studies 18

Co-authors: Atsushi Ohtsu Taroh Satoh Tomohiro Nishina Takayuki Yoshino Kei Muro Kensei Yamaguchi Yoshito Komatsu Toshihiko Doi
Cited by: Gastroenterology Oncology Pulmonary and Respiratory Medicine
Partner nations: Japan United States Germany

In The Last Decade

Akihito Tsuji

171 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2014 Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Peers

Countries citing papers authored by Akihito Tsuji

Since Specialization

Citations

This map shows the geographic impact of Akihito Tsuji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihito Tsuji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihito Tsuji more than expected).

Fields of papers citing papers by Akihito Tsuji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihito Tsuji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihito Tsuji. The network helps show where Akihito Tsuji may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Akihito Tsuji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Akihito Tsuji Line = papers co-authored together Akihito Tsuji links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study Kohei Shitara,Motohiro Tamiya,Kyoichi Okishio,Hisashi Hosaka,Katsunori Shinozaki,Nobuhiko Seki,Hiroki Hara,Yukiya Narita,Takeshi Shiraishi,Yosuke Tamura,Akihito Tsuji,Kunihiro Tsuji,Naohiro Watanabe,Hiroshi Tanaka,Toshifumi Yamaguchi,Kensei Yamaguchi,Hiroki Izumi,Yasunori Ushida,Hideaki Suna	2025	0
2	Third Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on diabetes and cancer: summary of the results of a questionnaire survey of oncologists and diabetologists—secondary publication Atsushi Goto,Ken Ohashi,Mitsuhiko Noda,Hiroshi Noto,Kohjiro Ueki,Manami Inoue,Rimei Nishimura,Shin Takahashi,Tatsuya Ioka,Masanobu Oshima,Kazutoshi Fujibayashi,Akihito Tsuji,Makoto Kodaira,Akiko Tamakoshi,Koshi Mimori,Yuko Tanabe,Eiji Hara,Keitaro Matsuo,Yoshinori Murakami,Hirotaka Watada	2024	0
3	Third Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer: Summary of the results of a questionnaire survey of oncologists and diabetologists—Secondary publication Atsushi Goto,Ken Ohashi,Mitsuhiko Noda,Hiroshi Noto,Kohjiro Ueki,Manami Inoue,Rimei Nishimura,Shin Takahashi,Tatsuya Ioka,Masanobu Oshima,Kazutoshi Fujibayashi,Akihito Tsuji,Makoto Kodaira,Akiko Tamakoshi,Koshi Mimori,Yuko Tanabe,Eiji Hara,Keitaro Matsuo,Yoshinori Murakami,Hirotaka Watada	2024	1
4	Validation of the Japanese Version of the Spiritual Care Competence Questionnaire Hiroko Shimizu,Eckhard Frick,Arndt Büssing,Hoshina Uehara,Akihito Tsuji,Keiko Matsumoto	2023	3
5	Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16 Hisateru Yasui,Y. Okita,Masato Nakamura,Takashi Sagawa,Takanori Watanabe,Kozo Kataoka,Dai Manaka,Kazuhiro Shiraishi,Naoya Akazawa,Tatsuya Okuno,Takaya Shimura,Manabu Shiozawa,Yu Sunakawa,Hirofumi Ota,Masahito Kotaka,Hiroomi Okuyama,Masahiro Takeuchi,Wataru Ichikawa,Masashi Fujii,Akihito Tsuji	2023	2
6	The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer Chiaki Inagaki,Ryo Matoba,Satoshi Yuki,Manabu Shiozawa,Akihito Tsuji,Eisuke Inoue,Kei Muro,Wataru Ichikawa,M. Fujii,Yu Sunakawa	2023	2
7	Novel endoscopic duodenal observation protocol based on Seven Pictures Rule for detecting duodenal neoplasms during esophagogastroduodenoscopy: Prospective observational study Kazuhiro Kozuka,Hideki Kobara,Takanori Matsui,Akihiko Fujisawa,Miwa Tatsuta,Mitsuyoshi Kobayashi,Mitsugu Yasuda,Kaho Nakatani,Naoya TADA,Taiga Chiyo,Nobuya Kobayashi,Tatsuo Yachida,Noriko Nishiyama,Shintaro Fujihara,Akihiro Kondo,Keiichi Okano,Akihito Tsuji,Tsutomu Masaki	2023	2
8	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives Gunnar Folprecht,Erika Martinelli,Thibault Mazard,Dominik Paul Modest,Akihito Tsuji,Regina Esser,Chiara Cremolini,Alfredo Falcone	2021	13
9	Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study) Masahito Kotaka,Shigeyoshi Iwamoto,Hironaga Satake,Daisuke Sakai,Toshihiro Kudo,Mutsumi Fukunaga,Ken Konishi,Yoshihito Ide,Taro Ikumoto,Akihito Tsuji,Yasushi Sano,Takeshi Kato,Naotoshi Sugimoto,Taroh Satoh,Akiyoshi Kanazawa,Takayasu Kurata,Takeharu Yamanaka,Naohiro Tomita	2020	4
10	Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan Misato Ogata,Masahito Kotaka,Takatsugu Ogata,Yukimasa Hatachi,Hisateru Yasui,Takeshi Kato,Akihito Tsuji,Hironaga Satake	2020	11
11	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer Masaaki Miyo,Takeshi Kato,Takayuki Yoshino,Takeharu Yamanaka,Hideaki Bando,Hironaga Satake,Kentaro Yamazaki,Hiroya Taniguchi,Eiji Oki,Masahito Kotaka,Koji Oba,Yoshinori Miyata,Kei Muro,Yoshito Komatsu,Hideo Baba,Akihito Tsuji	2020	8
12	Guidewire-assisted over-the-scope clip delivery method into the distal intestine: a case series Naoya TADA,Hideki Kobara,Noriko Nishiyama,Shintaro Fujihara,Tadayuki Takata,Kazuhiro Kozuka,Takanori Matsui,Nobuya Kobayashi,Taiga Chiyo,Koji Fujita,Joji Tani,Tatsuo Yachida,Akihito Tsuji,Keiichi Okano,Yasuyuki Suzuki,Daisuke Nakano,Akira Nishiyama,Tsutomu Masaki	2020	2
13	Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer Yasuhide Yamada,Wasaburo Koizumi,Kazuhiro Nishikawa,Masahiro Gotoh,Nozomu Fuse,Naotoshi Sugimoto,Tomohiro Nishina,Kenji Amagai,Keisho Chìn,Yasumasa Niwa,Akihito Tsuji,Hiroshi Imamura,Masahiro Tsuda,Hirofumi Yasui,Hirofumi Fujii,Kensei Yamaguchi,Hisateru Yasui,Shuichi Hironaka,Ken Shimada,Ichinosuke Hyodo	2019	12
14	Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER) Toshikazu Moriwaki,Yoshinori Sakai,Hiroyasu Ishida,Yoshiyuki Yamamoto,Shinji Endo,Hideaki Kuramochi,Mikio Sato,Yukimasa Hatachi,Yoshiaki Bando,Takashi Maeba,Kazuto Ikezawa,Mitsuo Shimada,Kenji Amagai,Masamitsu Morimoto,Kazuma Kobayashi,Akihito Tsuji,Tomohiro Nishina,Ichinosuke Hyodo	2019	3
15	Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer Yu Sunakawa,Kaoru Mogushi,Heinz‐Josef Lenz,Wu Zhang,Akihito Tsuji,Takehiro Takahashi,Tadamichi Denda,Ken Shimada,Mitsugu Kochi,Masato Nakamura,Masahito Kotaka,Yoshihiko Segawa,Hiroaki Tanioka,Yuji Negoro,Miriana Moran,Stephanie H. Astrow,Jack Hsiang,Craig Stephens,Masashi Fujii,Wataru Ichikawa	2018	3
16	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1 Yasunori Sato,Hideki Ueno,Tatsuya Ioka,Shinichi Ohkawa,Masafumi Ikeda,T Shimamura,Akihito Tsuji,Yoshiaki Tsuchiya,Junji Furuse,Hiroshi Ishii,Ken Furuya,Haruo Iguchi,Yoshihiro Saito,Nahoko Kaniwa,Jun‐ichi Sawada,Hiromi Sakamoto,Akihiro Sekine,Takuji Okusaka,Teruhiko Yoshida	2018	3
17	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study Eiji Oki,Takeshi Kato,Hideaki Bando,Takayuki Yoshino,Kei Muro,Hiroya Taniguchi,Yoshinori Kagawa,Kentaro Yamazaki,Tatsuro Yamaguchi,Akihito Tsuji,Shigeyoshi Iwamoto,Goro Nakayama,Yasunori Emi,Tetsuo Touyama,Masato Nakamura,Masahito Kotaka,Hideki Sakisaka,Takeharu Yamanaka,Akiyoshi Kanazawa	2018	32
18	Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials Yu Sunakawa,Wataru Ichikawa,Akihito Tsuji,Tadamichi Denda,Yoshihiko Segawa,Yuji Negoro,Ken Shimada,Mitsugu Kochi,Masato Nakamura,Masahito Kotaka,Hiroaki Tanioka,Akinori Takagane,Satoshi Tani,Tatsuro Yamaguchi,Takanori Watanabe,Masahiro Takeuchi,Masashi Fujii,Toshifusa Nakajima	2016	37
19	RETROSPECTIVE STUDY REGARDING THE EFFICACY OF 2ND OR HIGHER LINE CHEMOTHERAPY OF PATIENTS IN ADVANCED OR RECURRENT GASTRIC CANCER (ARGC) AFTER THE FAILURE OF S-1 OR S-1 COMBINATION CHEMOTHERAPY (S plus alpha) Tadashi Horimi,Satoshi Morita,Y. Hata,Akihito Tsuji,Koji Kobayashi	2010	2
20	COLONOSCOPIC POLYPECTOMY OF JUVENILE POLYPS IN INFANTS AND CHILDREN Motohiro Takasaki,A Hirano,Masahiro Takamatsu,Akihito Tsuji,Keita Inoue,Taku Tanaka,Yukio Yorimitsu,Sojiro Morita,Isao Takeda,Hirohumi Tokuoka,Tadashi Horimi	1996	1

About Akihito Tsuji

Akihito Tsuji is a scholar working on Oncology, Gastroenterology and Pulmonary and Respiratory Medicine, having authored 184 papers that have together received 2.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (122 papers), Gastric Cancer Management and Outcomes (83 papers), Cancer Treatment and Pharmacology (48 papers), Lung Cancer Treatments and Mutations (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Gastrointestinal Tumor Research and Treatment (18 papers) and Pancreatic and Hepatic Oncology Research (17 papers). The work is most often cited by research in Gastroenterology (418 citations), Oncology (1.9k citations) and Pulmonary and Respiratory Medicine (1.6k citations). Akihito Tsuji has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Atsushi Ohtsu, Taroh Satoh, Tomohiro Nishina, Takayuki Yoshino, Kei Muro, Kensei Yamaguchi, Yoshito Komatsu, Toshihiko Doi, Hideo Baba and Hyun Cheol Chung.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact